サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1498775

RSウイルス（呼吸器合胞体ウイルス）治療薬市場：タイプ別、用途別、エンドユーザー別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測

Respiratory Syncytial Virus Drugs Market, By Type, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 322 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
RSウイルス（呼吸器合胞体ウイルス）治療薬市場：タイプ別、用途別、エンドユーザー別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年06月04日
発行: AnalystView Market Insights
ページ情報: 英文 322 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

RSウイルス（呼吸器合胞体ウイルス）治療薬市場規模は2023年に58億9,020万米ドルとなり、2024年から2032年にかけてCAGR 12.90%で拡大

RSウイルス（呼吸器合胞体ウイルス）治療薬市場- 市場力学

RSV感染と診断に関する意識の高まりが市場需要を促進する見込み

RSVに関する知識の増加や診断方法の改善により、感染診断の頻度や早期化が進み、RSV治療薬や予防療法に対する需要が増加しています。小さな子どもから高齢者まで、呼吸器疾患の原因の多くはRSVです。RSV感染症の高い有病率と再発性により、効率的な治療と予防戦略が必要とされています。重要な動機付けとしては、新規抗ウイルス薬、モノクローナル抗体、ワクチン接種の創出と認可が挙げられます。効率的な治療が導入され、代替治療が革新されていることから、市場の成長が期待されています。

効率的なRSV治療薬へのニーズは、重症RSV感染症にかかりやすい高齢化社会が後押ししています。世界人口の高齢化に伴い、RSVの罹患率が上昇し、市場の需要を押し上げることが予想されます。バイオテクノロジーや医薬品の発展により、新しい治療法や予防接種の開発も容易になってきています。RSV治療薬の入手可能性と有効性は、このような技術進歩によって改善され、市場拡大を後押ししています。新薬やワクチンに対する規制当局の承認は、業界を大きく後押ししています。RSV治療薬に対するファスト・トラック指定や有利な規制条件は、市場の成長に貢献する可能性があります。

RSウイルス（呼吸器合胞体ウイルス）治療薬市場-主要インサイト

当社のリサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約12.90%のCAGRで毎年成長すると推定されます。

タイプ別セグメンテーションに基づくと、承認薬セグメントは、USFDAの支持的な規制により、2023年に最大の市場シェアを示すと予測されました。

用途別では、臨床試験および治療におけるウイルス薬の需要が高いことから、臨床診断分野が2023年の主要用途でした。

エンドユーザーセグメンテーションに基づくと、呼吸器疾患の治療に対する高い需要により、病院セグメントが2023年の主要エンドユーザーでした。

地域別では、北米は高度なヘルスケアインフラの存在により、2023年に収益でリードしました。

RSウイルス（呼吸器合胞体ウイルス）治療薬市場-セグメンテーション分析：

RSウイルス（呼吸器合胞体ウイルス）治療薬の世界市場は、タイプ、用途、エンドユーザー、地域に基づいて区分されます。

タイプ別では、承認薬と適応外薬に分類されます。承認薬セグメントが市場を独占しています。技術革新とFDAの規制がこの分野の成長を後押ししています。

市場は用途によって3つに分類される：臨床診断、ラボラトリー、その他。オフライン店舗部門が市場を独占しています。シンシチアルウイルス感染症の流行が拡大していることが、市場成長への有力な需要となっています。

市場はエンドユーザー別に病院、診療所、その他の3つに分類されます。病院セグメントが市場を独占しており、予測期間中も高い優位性を維持すると予想されます。ヘルスケアと先進インフラへの多額の投資が市場の成長を加速させています。

RSウイルス（呼吸器合胞体ウイルス）治療薬市場-地理的洞察

地域的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。世界市場を独占しているのは北米です。北米は研究開発費が多く、医療インフラが整備され、ヘルスケア支出が多いため、市場シェアが高く、RSV治療薬の最大市場の1つとなっています。

RSウイルス（呼吸器合胞体ウイルス）治療薬市場-競合情勢：

RSウイルス（呼吸器合胞体ウイルス）治療薬市場の競争は中程度です。同市場の有力企業は、製薬会社、学術機関、ヘルスケアプロバイダー間の提携に注力しており、RSV治療薬の創出と普及を促進し、市場を拡大しています。

目次

第1章 RSウイルス（呼吸器合胞体ウイルス）治療薬市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 RSウイルス（呼吸器合胞体ウイルス）治療薬の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 RSウイルス（呼吸器合胞体ウイルス）治療薬産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 RSウイルス（呼吸器合胞体ウイルス）治療薬市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 RSウイルス（呼吸器合胞体ウイルス）治療薬市場情勢

  • RSウイルス（呼吸器合胞体ウイルス）治療薬市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 RSウイルス（呼吸器合胞体ウイルス）治療薬市場：タイプ別

  • 概要
    • タイプ別セグメントシェア分析
    • 承認医薬品
    • 適応外医薬品

第8章 RSウイルス（呼吸器合胞体ウイルス）治療薬市場：用途別

  • 概要
    • 用途別セグメントシェア分析
    • 臨床診断
    • ラボ
    • その他

第9章 RSウイルス（呼吸器合胞体ウイルス）治療薬市場：エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院
    • クリニック
    • その他

第10章 RSウイルス（呼吸器合胞体ウイルス）治療薬市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：RSウイルス（呼吸器合胞体ウイルス）治療薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • AbbVie Inc.
    • Swedish Orphan Biovitrum AB
    • AstraZeneca
    • Johnson &Johnson Services Inc.
    • Sanofi
    • Merck &Co., Inc.
    • Bausch Health Companies Inc.
    • Celltrion Inc.
    • mAbxience
    • Enanta Pharmaceuticals, Inc.
    • Moderna, Inc.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novavax, Inc.
    • Roche Holding AG
    • その他

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Respiratory Syncytial Virus Drugs Market: Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Respiratory Syncytial Virus Drugs Market, by Type 2019-2032 (USD Million)
  • TABLE Respiratory Syncytial Virus Drugs Market: Application Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Respiratory Syncytial Virus Drugs Market, by Application 2019-2032 (USD Million)
  • TABLE Respiratory Syncytial Virus Drugs Market: End User Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by End User
  • TABLE Global Respiratory Syncytial Virus Drugs Market, by End User 2019-2032 (USD Million)
  • TABLE Respiratory Syncytial Virus Drugs Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Respiratory Syncytial Virus Drugs Market, by Region 2019-2032 (USD Million)
  • TABLE North America Respiratory Syncytial Virus Drugs Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Respiratory Syncytial Virus Drugs Market, by Type, 2019-2032 (USD Million)
  • TABLE North America Respiratory Syncytial Virus Drugs Market, by Application, 2019-2032 (USD Million)
  • TABLE North America Respiratory Syncytial Virus Drugs Market, by End User, 2019-2032 (USD Million)
  • TABLE Europe Respiratory Syncytial Virus Drugs Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Respiratory Syncytial Virus Drugs Market, by Type, 2019-2032 (USD Million)
  • TABLE Europe Respiratory Syncytial Virus Drugs Market, by Application, 2019-2032 (USD Million)
  • TABLE Europe Respiratory Syncytial Virus Drugs Market, by End User, 2019-2032 (USD Million)
  • TABLE Asia Pacific Respiratory Syncytial Virus Drugs Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Respiratory Syncytial Virus Drugs Market, by Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Respiratory Syncytial Virus Drugs Market, by Application, 2019-2032 (USD Million)
  • TABLE Asia Pacific Respiratory Syncytial Virus Drugs Market, by End User, 2019-2032 (USD Million)
  • TABLE Latin America Respiratory Syncytial Virus Drugs Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Respiratory Syncytial Virus Drugs Market, by Type, 2019-2032 (USD Million)
  • TABLE Latin America Respiratory Syncytial Virus Drugs Market, by Application, 2019-2032 (USD Million)
  • TABLE Latin America Respiratory Syncytial Virus Drugs Market, by End User, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Respiratory Syncytial Virus Drugs Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Respiratory Syncytial Virus Drugs Market, by Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Respiratory Syncytial Virus Drugs Market, by Application, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Respiratory Syncytial Virus Drugs Market, by End User, 2019-2032 (USD Million)
目次
Product Code: ANV2946

REPORT HIGHLIGHT

Respiratory Syncytial Virus Drugs Market size was valued at USD 5,890.20 Million in 2023, expanding at a CAGR of 12.90% from 2024 to 2032.

A frequent virus that affects the respiratory system is called Respiratory Syncytial Virus (RSV), and it usually affects small children, the elderly, and people with weakened immune systems. Several medications and therapies are used to treat RSV infection.

Respiratory Syncytial Virus Drugs Market- Market Dynamics

Growing awareness about RSV infections and diagnosis is expected to propel market demand

The demand for RSV medications and preventive therapy has increased because of increased knowledge of RSV and improvements in diagnostic methods, which have led to more frequent and earlier infection diagnoses. For both small children and the elderly, respiratory illnesses are mostly caused by RSV. The need for efficient treatments and preventive strategies is driven by the high prevalence and recurrent nature of RSV infections. Important motivators include the creation and licensure of novel antiviral medications, monoclonal antibodies, and vaccinations. The market is expected to grow due to efficient treatments being introduced and treatment alternatives being innovated.

The need for efficient RSV medications is driven by the aging population, who are more vulnerable to severe RSV infections. It is anticipated that as the world's population ages, RSV incidence will climb in this group, driving up market demand. Novel therapies and vaccinations are becoming easier to develop because of developments in biotechnology and pharmaceuticals. The availability and efficacy of RSV medications are improved by these technological advancements, which propels market expansion. Regulatory approvals for novel medications and vaccines provide the industry a big boost. Fast-track designations and favorable regulatory conditions for RSV medicines can contribute to the growth of the market.

Respiratory Syncytial Virus Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.90% over the forecast period (2024-2032)

Based on Type segmentation, the approved drugs segment was predicted to show maximum market share in the year 2023, owing to supportive USFDA regulations.

Based on Application segmentation, the clinical diagnostics segment was the leading Application in 2023, due to the high demand for viral drugs in clinical trials & treatment.

Based on End User segmentation, the hospital segment was the leading End User in 2023, owing to high demand for the treatment of respiratory disorders.

On the basis of region, North America was the leading revenue generator in 2023, owing to presence of advanced healthcare infrastructure.

Respiratory Syncytial Virus Drugs Market- Segmentation Analysis:

The Global Respiratory Syncytial Virus Drugs Market is segmented on the basis of Type, Application, End User, and Region.

The market is divided into two categories based on Type: approved drugs and off-label drugs. The approved drugs segment dominates the market. Technological innovation along with supportive FDA regulations is enhancing the segment growth.

The market is divided into three categories based on the Application: clinical diagnostics, laboratories, and others. The offline stores segment dominates the market. The growing prevalence of syncytial viral infections is a compelling demand for market growth.

The market is divided into three categories based on End Users: hospitals, clinics, and others. The hospital segment dominates the market and is expected to maintain its high dominance during the forecast period. Significant investment in healthcare and advanced infrastructure is accelerating the growth of the market.

Respiratory Syncytial Virus Drugs Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is dominating the global market. The region holds a larger market share because of its substantial R&D expenditures, sophisticated medical infrastructure, and high healthcare spending, North America is one of the biggest markets for RSV medications.

Respiratory Syncytial Virus Drugs Market- Competitive Landscape:

The respiratory syncytial virus drugs market is moderately competitive. Prominent players in the market focus on partnerships among pharmaceutical firms, academic institutions, and healthcare providers might expedite the creation and dissemination of RSV medications, thereby augmenting the market. Some of the major companies include AstraZeneca, Johnson & Johnson, Sanofi, Merck & Co., and newer companies like Moderna. Smaller companies are looking to offer innovative solutions and get USFDA approvals.

Recent Developments:

In February 2024, GSK plc received the USFDA approvals to expand their respiratory syncytial virus vaccination for people over 50.

In May 2023, Pfizer, Inc. introduced a bivalent RSV vaccine with USFDA approval for preventing respiratory tract illness.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET KEY PLAYERS

  • AbbVie Inc.
  • Swedish Orphan Biovitrum AB
  • AstraZeneca
  • Johnson & Johnson Services Inc.
  • Sanofi
  • Merck & Co., Inc.
  • Bausch Health Companies Inc.
  • Celltrion Inc.
  • mAbxience
  • Enanta Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novavax, Inc.
  • Roche Holding AG
  • Others

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019-2032

  • Approved drugs
  • Off-label drugs

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

  • Clinical diagnostics
  • Laboratories
  • Others

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019-2032

  • Hospitals
  • Clinics
  • Others

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Respiratory Syncytial Virus Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Respiratory Syncytial Virus Drugs Market Snippet by Type
    • 2.1.2. Respiratory Syncytial Virus Drugs Market Snippet by Application
    • 2.1.3. Respiratory Syncytial Virus Drugs Market Snippet by End User
    • 2.1.4. Respiratory Syncytial Virus Drugs Market Snippet by Country
    • 2.1.5. Respiratory Syncytial Virus Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Respiratory Syncytial Virus Drugs Key Market Trends

  • 3.1. Respiratory Syncytial Virus Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Respiratory Syncytial Virus Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Respiratory Syncytial Virus Drugs Market Opportunities
  • 3.4. Respiratory Syncytial Virus Drugs Market Future Trends

4. Respiratory Syncytial Virus Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Respiratory Syncytial Virus Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Respiratory Syncytial Virus Drugs Market Landscape

  • 6.1. Respiratory Syncytial Virus Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Respiratory Syncytial Virus Drugs Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Approved drugs
    • 7.1.3. Off-label drugs

8. Respiratory Syncytial Virus Drugs Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Clinical diagnostics
    • 8.1.3. Laboratories
    • 8.1.4. Others

9. Respiratory Syncytial Virus Drugs Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Clinics
    • 9.1.4. Others

10. Respiratory Syncytial Virus Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Respiratory Syncytial Virus Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Respiratory Syncytial Virus Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Respiratory Syncytial Virus Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Respiratory Syncytial Virus Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Respiratory Syncytial Virus Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Respiratory Syncytial Virus Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc.
    • 11.2.2. Swedish Orphan Biovitrum AB
    • 11.2.3. AstraZeneca
    • 11.2.4. Johnson & Johnson Services Inc.
    • 11.2.5. Sanofi
    • 11.2.6. Merck & Co., Inc.
    • 11.2.7. Bausch Health Companies Inc.
    • 11.2.8. Celltrion Inc.
    • 11.2.9. mAbxience
    • 11.2.10. Enanta Pharmaceuticals, Inc.
    • 11.2.11. Moderna, Inc.
    • 11.2.12. Pfizer Inc.
    • 11.2.13. GlaxoSmithKline plc
    • 11.2.14. Novavax, Inc.
    • 11.2.15. Roche Holding AG
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us